celastrol has been researched along with alpha-synuclein in 2 studies
| Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) | Studies (alpha-synuclein) | Trials (alpha-synuclein) | Recent Studies (post-2010) (alpha-synuclein) |
|---|---|---|---|---|---|
| 885 | 1 | 741 | 10,821 | 29 | 8,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheung, AKL; Li, M; Ng, L; Su, C; Wang, X; Yang, C | 1 |
| Aouti, S; Jos, S; K N, K; Kamariah, N; Mythri, RB; Padavattan, S; Padmanabhan, B; Prasad, TK; R, K; Unni, S | 1 |
2 other study(ies) available for celastrol and alpha-synuclein
| Article | Year |
|---|---|
Celastrol Downmodulates Alpha-Synuclein-Specific T Cell Responses by Mediating Antigen Trafficking in Dendritic Cells.
Topics: Aged; alpha-Synuclein; Dendritic Cells; Humans; Neurodegenerative Diseases; Parkinson Disease; Pentacyclic Triterpenes; T-Lymphocytes | 2022 |
High-affinity binding of celastrol to monomeric α-synuclein mitigates in vitro aggregation.
Topics: alpha-Synuclein; Humans; Parkinson Disease; Pentacyclic Triterpenes | 2023 |